Ptc Therapeutics (PTCT)

Feb 20, 2025, 8:00 AM EST - 2 days ago

PTC Therapeutics to Participate in Upcoming Investor Conferences

Feb 19, 2025, 7:00 AM EST - 3 days ago

PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's Ataxia

Feb 13, 2025, 8:00 AM EST - 9 days ago

PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results

Jan 13, 2025, 4:30 PM EST - 5 weeks ago

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 13, 2025, 9:00 AM EST - 5 weeks ago

PTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43rd Annual J.P. Morgan Healthcare Conference

Dec 23, 2024, 8:00 AM EST - 2 months ago

PTC Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 19, 2024, 8:00 AM EST - 2 months ago

PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia

Dec 2, 2024, 1:50 PM EST - 2 months ago

PTC Therapeutics Stock Soars on Novartis Licensing Agreement

Dec 2, 2024, 12:58 PM EST - 2 months ago

PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program

NVS

Dec 2, 2024, 7:14 AM EST - 2 months ago

PTC Therapeutics signs up to $1.9 billion licensing deal with Novartis

NVS

Dec 2, 2024, 7:00 AM EST - 2 months ago

PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program

NVS

Nov 27, 2024, 7:51 AM EST - 3 months ago

PTC Therapeutics Ends Utreloxastat Development After Rare Neurodegenerative Disease Trial Misses Goal, Analyst Maintains Outperform With Focus On Sepiapterin, Huntington's Programs

Nov 27, 2024, 7:00 AM EST - 3 months ago

PTC Therapeutics Enters into Agreement to Sell Priority Review Voucher for $150 Million

Nov 26, 2024, 4:41 PM EST - 3 months ago

PTC Therapeutics discontinues development of ALS drug after trial failure

Nov 26, 2024, 4:30 PM EST - 3 months ago

PTC Therapeutics Announces Topline Results of CardinALS Trial of Utreloxastat in ALS Patients

Nov 13, 2024, 6:09 PM EST - 3 months ago

US FDA approves PTC Therapeutics' gene therapy for ultra-rare disorder

Nov 13, 2024, 6:02 PM EST - 3 months ago

PTC Therapeutics Announces FDA Approval of AADC Deficiency Gene Therapy

Nov 7, 2024, 11:19 PM EST - 3 months ago

PTC Therapeutics, Inc. (PTCT) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:01 PM EST - 3 months ago

PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Nov 4, 2024, 4:30 PM EST - 3 months ago

PTC Therapeutics to Participate at Upcoming Investor Conferences

Oct 30, 2024, 7:00 AM EDT - 4 months ago

PTC Therapeutics Announces FDA Acceptance of Translarna™ NDA Resubmission

Oct 24, 2024, 7:00 AM EDT - 4 months ago

PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2024 Financial Results

Oct 18, 2024, 6:30 AM EDT - 4 months ago

CHMP Maintains Negative Opinion on Translarna™ Reexamination

Oct 14, 2024, 4:30 PM EDT - 4 months ago

PTC Therapeutics Announces FDA Target Regulatory Action Date for Sepiapterin and Lancet Publication of Phase 3 Trial Results

Oct 8, 2024, 8:00 AM EDT - 4 months ago

PTC Therapeutics Announces Positive Results from Long-Term Treatment Studies and Updates on Regulatory Progress for Vatiquinone Friedreich Ataxia Program

Oct 1, 2024, 9:00 AM EDT - 5 months ago

PTC Therapeutics Announces FDA Acceptance for Filing of NDA for Sepiapterin for the Treatment of Pediatric and Adult Phenylketonuria Patients

Sep 26, 2024, 8:00 AM EDT - 5 months ago

FDA Grants Fast Track Designation to PTC518 Huntington's Disease Program

Sep 12, 2024, 4:13 PM EDT - 5 months ago

PTC Therapeutics: Positive HD Data Along With NDA Submission Brings Further Value

Aug 9, 2024, 11:53 AM EDT - 7 months ago

PTC Therapeutics, Inc. (PTCT) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 4:01 PM EDT - 7 months ago

PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Jul 30, 2024, 8:00 AM EDT - 7 months ago

PTC Therapeutics Announces Sepiapterin NDA Submission to FDA

Jul 25, 2024, 4:30 PM EDT - 7 months ago

PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results

Jul 15, 2024, 2:00 PM EDT - 7 months ago

PTC Therapeutics, Inc. (PTCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Jun 28, 2024, 6:00 AM EDT - 8 months ago

CHMP Issues Negative Opinion on Translarna™ Following European Commission Request for Review

Jun 20, 2024, 6:30 AM EDT - 8 months ago

Interim PIVOT-HD Results Demonstrate Evidence of Favorable CNS Biomarker and Clinical Effects at Month 12 in Huntington's Disease Patients

May 29, 2024, 8:00 AM EDT - 9 months ago

PTC Therapeutics to Participate at Upcoming Investor Conference

May 28, 2024, 8:30 AM EDT - 9 months ago

PTC Therapeutics Announces Validation of Sepiapterin European MAA

May 20, 2024, 7:00 AM EDT - 9 months ago

PTC Therapeutics Announces European Commission Returns Translarna™ Opinion to CHMP For Re-evaluation

May 14, 2024, 3:35 PM EDT - 10 months ago

PTC Therapeutics: Multiple Regulatory Submissions Along With Data Cuts

May 14, 2024, 7:30 AM EDT - 10 months ago

PTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza™

Apr 25, 2024, 11:52 PM EDT - 10 months ago

PTC Therapeutics, Inc. (PTCT) Q1 2024 Earnings Call Transcript

Apr 25, 2024, 4:05 PM EDT - 10 months ago

PTC Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

Apr 11, 2024, 8:00 AM EDT - 11 months ago

PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results

Mar 28, 2024, 8:30 AM EDT - 11 months ago

PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA